

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

Rabbit IgG anti-Human IgG (F(ab)2)-FITC, MinX none DNA-SEC-182579

Article Name	Rabbit IgG anti-Human IgG (F(ab)2)-FITC, MinX none
Biozol Catalog Number	DNA-SEC-182579
Supplier Catalog Number	SEC-182579
Alternative Catalog Number	DNA-SEC-182579
Manufacturer	dianova
Host	Rabbit
Category	Antikörper
Application	FLISA,FACS,IF
Species Reactivity	Human
Immunogen	Human IgG F(ab)2 fragment
Conjugation	FITC
Format	IgG
Target Specificity	IgG (F(ab')2)
Cross-Adsorption (MinX)	no cross-adsorbtion
Product Description	Anti-Human IgG F(ab)2 Fluorescein Antibody generated in rabbit recognizes the dimeric Fab portion of the human IgG molecule. Human IgG F(ab)2 is a proteolytic fragment of immunoglobulin G (IgG) obtained by limited digestion with the enzyme pepsin und...
Clonality	Polyclonal

Concentration	10 mg/mL
Isotype	Ig
Buffer	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Purity	This product is an IgG fraction antibody purified from monospecific antiserum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against the buffer stated above. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-fluorescein, anti-Rabbit Serum, Human IgG, Human IgG F(ab') ₂ and Human Serum. No reaction was observed against Human IgG F(c).
Form	Lyophilized
Formula	20 mM K ₃ PO ₄ , 150 mM NaCl, pH 7.2, lyophilisate, Azide/BSA free
Target	Human
Antibody Type	Secondary Antibody
Application Dilute	FLISA Dilution: 1:10,000 - 1:50,000, Flow Cytometry Dilution: 1:500 - 1:2,500, IF Microscopy Dilution: 1:1,000 - 1:5,000
Application Notes	Anti-Human IgG F(ab') ₂ Fluorescein Antibody is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.